adrian cosa retweetledi

#GSK R&D keeps delivering for longer term revenue generation. You have to have a long term view on this but I believe dividends plus capital gains will be worth the wait. Trades at significant discount to peers.
GSK PLC - GSK 5-in-1 meningitis vaccine approved by US FDA #GSK @GSK voxmarkets.co.uk/rns/announceme… #voxmarkets undefined
English






















